Medicaid coverage for gender-affirming care depends heavily on which state you live in, your age, and what type of service you need. As of the most recent data, 25 state Medicaid programs cover gender-affirming hormone therapy for adults, while 3 states explicitly exclude it and 13 have no clear policy on the books. For minors, the landscape is more restrictive: 27 states do not provide Medicaid coverage for gender-affirming procedures for children, and federal rulemaking proposed in 2025 would prohibit federal Medicaid and CHIP funding for these services for anyone under 18.
How Coverage Varies by State
There is no single national Medicaid policy on gender-affirming care. Each state administers its own Medicaid program within a federal framework, which means coverage rules differ dramatically depending on where you live. Some states explicitly include gender-affirming services in their Medicaid benefits. Others have passed laws that specifically ban Medicaid reimbursement for some or all of these services. And a significant number of states simply haven’t addressed the question in their statutes or official policy, leaving coverage in a gray area.
Of the 25 states that cover gender-affirming hormone therapy, 10 require prior authorization before treatment can begin. That means your provider needs to submit documentation showing the treatment is medically necessary, and the state Medicaid program must approve it before you can fill a prescription or begin care. The remaining 15 states that cover hormones do so without that extra step. Alabama, Hawaii, and Texas explicitly exclude coverage of gender-affirming hormone therapy for adults.
Surgical coverage is even more uneven. A review of state Medicaid programs found that the most commonly covered procedures were chest surgery (such as mastectomy or breast reduction) and hysterectomy, each covered in about 17 states. Reversal surgeries were the most frequently excluded procedure, with 12 states specifically listing them as noncovered. Other surgical categories, including genital reconstruction, craniofacial procedures, and related operations, vary widely from state to state.
Coverage for Minors
Coverage for people under 18 is significantly more restricted than for adults, and those restrictions have been accelerating. Several states have passed laws that specifically prohibit the use of Medicaid or public funds for gender-affirming care for minors. Arkansas bans public funds, including Medicaid, from being used for gender-affirming care for minors and prohibits funding for organizations that provide it. Texas bars CHIP and Medicaid from covering gender-affirming surgery or prescriptions for minors. Missouri goes further, prohibiting Medicaid funds for both surgical and prescription gender-affirming care for minors and adults. North Carolina, South Carolina, and Kansas have enacted similar restrictions targeting minors specifically.
At the federal level, CMS proposed a rule in late 2025 that would prohibit federal Medicaid funding for what the agency termed “sex-rejecting procedures” for anyone under 18. The same prohibition would apply to CHIP funding for individuals under 19. If finalized, this rule would override state-level decisions to cover these services for minors, even in states that currently do so. Approximately 17 state Medicaid programs were covering these procedures for children at the time the rule was proposed.
What Services Are Involved
Gender-affirming care covered by Medicaid generally falls into three categories: mental health services, hormone therapy, and surgery. Mental health support, including therapy and assessments related to gender dysphoria, is the most widely available and least controversial category. Most state Medicaid programs cover behavioral health services broadly, and gender-related counseling typically falls within that scope.
Hormone therapy includes estrogen, anti-androgens, and progestins (used for feminizing effects) as well as testosterone and related agents (used for masculinizing effects). None of these medications are exclusively prescribed for gender-affirming purposes. They’re all approved for other medical conditions, which means state Medicaid formularies include them regardless of their stance on gender-affirming care. The coverage question is really about whether your state will authorize these drugs specifically for the treatment of gender dysphoria. Under federal law, state Medicaid programs are generally required to cover all drugs from manufacturers participating in the federal Medicaid Drug Rebate program, which has created legal tension with states that try to exclude these medications for gender-related use.
Surgical procedures are the least commonly covered and the most likely to require extensive documentation. Where coverage exists, prior authorization is standard, and you’ll typically need letters from mental health providers, a documented history of gender dysphoria, and evidence that you’ve met specific clinical criteria before approval.
The Legal Picture
Courts have been actively shaping this landscape. A federal district court in Florida ruled that a state law banning Medicaid reimbursement for gender-affirming prescriptions and procedures violated the Equal Protection Clause and federal anti-discrimination law under Section 1557 of the Affordable Care Act. In April 2024, the Fourth Circuit Court of Appeals affirmed in an 8-to-6 decision that both West Virginia and North Carolina health plans were subject to intermediate scrutiny under the Equal Protection Clause, meaning the states needed a strong justification for excluding coverage of gender dysphoria treatments. The court found they didn’t meet that standard. The Eighth Circuit similarly upheld a preliminary injunction blocking a state law that restricted gender dysphoria treatment for minors on equal protection grounds.
These rulings have generally pushed against blanket exclusions, but they apply only within their respective jurisdictions and can be overridden by higher court decisions or new federal policy. The current federal administration has moved to reverse earlier interpretations that treated gender dysphoria as a disability under Section 504 of the Rehabilitation Act. A proposed revision would clarify that gender dysphoria (when not resulting from a physical impairment) does not qualify as a disability under that law, which would remove one legal basis that advocates have used to challenge coverage exclusions.
How to Check Your State’s Policy
Because coverage rules change frequently, the most reliable way to determine what your state Medicaid program covers is to contact your state Medicaid office directly or check with a local provider who works with transgender patients. KFF maintains a policy tracker that maps state-level restrictions on gender-affirming care, which can serve as a starting point. Your managed care plan, if you’re enrolled in one, may have its own coverage guidelines that are more or less generous than the state’s baseline policy.
If your state Medicaid program denies a claim for gender-affirming care, you have the right to appeal. Medicaid enrollees are entitled to a fair hearing process under federal law, and some of the court rulings mentioned above originated as challenges to individual coverage denials. Advocacy organizations like the National Center for Transgender Equality and Lambda Legal maintain resources for navigating Medicaid denials and connecting with legal support.